# US 2026/0294996 A1 · Compositions containing kratom compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0294996 A1
- Document ID: US20260294996A1
- Status: Published application
- Kind: A1
- Application number: 19/690,811
- Filed: 2026-05-28
- Published: 2026-10-01
- Earliest claimed: 2019-10-16
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R. CHADEAYNE
- Web page: https://patentgrep.com/patent/US20260294996A1

## CPC

- A61K 36/74: Rubiaceae (Madder family)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are compositions containing (a) a purified kratom compound chosen from the following: 7-Hydroxymitragynine, Mitragynine, Paynantheine, Speciociliatine, Speciogynine, Ajmalicine, Ciliaphylline, Corynantheidine, Corynoxine A, Corynoxine B, Isomitraphylline, Isorhynchophylline, Mitraphylline, Rhynchophylline, Speciophylline, Speciofoline, Epicatechin, 7-Hydroxyspecioliatine, 9-Hydroxycorynantheidine, Corynoxeine, Isopteropodine, Isorhynchophylline Oxindole, Tetrahydroalstonine, Mitragynine Oxindole B, and Mitragynine Oxindole A or the salts of these kratom compounds; and (b) a second active compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder.

## Claims

### Claim 1

An engineered and unnatural composition comprising:
(a) a first purified kratom compound; and
(b) a second purified kratom compound,
wherein the first and the second purified kratom compounds have been separated from plant material and are substantially free from non-alkaloid plant matter,
wherein the first and the second purified kratom compounds are present in the composition in a definite, chemically defined, non-natural molar ratio, and
wherein the first and the second purified kratom compounds present in the composition are of known purity and in known amounts, thereby enabling administration of consistent amounts of the first and the second purified kratom compounds to a subject across different portions taken from the same composition.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the first purified kratom compound is mitragynine and the second purified kratom compound is 7-hydroxymitragynine.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising an excipient.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising:
a purified terpene,
wherein the purified terpene is present in the composition in a definite, chemically defined, non-natural molar ratio.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the purified terpene is selected from limonene, linalool, eugenol, geraniol, citronellol, pinene, beta-myrcene, carvone, anethole, and menthol.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition is substantially free from a third kratom compound that is different than the first and the second purified kratom compounds.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the third kratom compound that the composition is substantially free from is 7-hydroxymitragynine.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the first and the second purified kratom compounds are independently selected from the group consisting of Mitragynine, Paynantheine, Speciociliatine, Speciogynine, Ajmalicine, Ciliaphylline, Corynantheidine, Corynoxine A, Corynoxine B, Isomitraphylline, Isorhynchophylline, Mitraphylline, Rhynchophylline, Speciophylline, Speciofoline, Epicatechin, 7-Hydroxyspecioliatine, 9-Hydroxycorynantheidine, Corynoxeine, Isopteropodine, Isorhynchophylline Oxindole, Tetrahydroalstonine, Mitragynine Oxindole B, Mitragynine Oxindole A, and a salt thereof, and wherein the third kratom compound that the composition is substantially free from is 7-hydoxymitragynine.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the first and the second purified kratom compounds are independently selected from the group consisting of 7-Hydroxymitragynine, Mitragynine, Paynantheine, Speciociliatine, Speciogynine, Ajmalicine, Ciliaphylline, Corynantheidine, Corynoxine A, Corynoxine B, Isomitraphylline, Isorhynchophylline, Mitraphylline, Rhynchophylline, Speciophylline, Speciofoline, Epicatechin, 7-Hydroxyspecioliatine, 9-Hydroxycorynantheidine, Corynoxeine, Isopteropodine, Isorhynchophylline Oxindole, Tetrahydroalstonine, Mitragynine Oxindole B, Mitragynine Oxindole A, and a salt thereof.
